Hypoglycemia Associated Autonomic Failure in Type 1 DM
Information source: Vanderbilt University
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 1 Diabetes
Intervention: Fluoxetine (Drug); Placebo (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Vanderbilt University Official(s) and/or principal investigator(s): Stephen N. Davis, MD, Principal Investigator, Affiliation: Vanderbilt University
Summary
It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on
hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of
blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et
al., 1996). Because of the increased prevalence of depression in those with diabetes, it is
critical to discover what affect the antidepressant therapy may have on counterregulatory
responses to hypoglycemia. This study hypothesizes that chronic administration of SSRIs may
result in a blunted counterregulatory response to hypoglycemia, thereby leaving individuals
more susceptible to hypoglycemia.
Clinical Details
Official title: Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6
Study design: Other, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Primary outcome: Catecholamine measures
Detailed description:
Because selective serotonin reuptake inhibitors are commonly prescribed to treat depression,
it is vital to understand how these antidepressants affect hypoglycemia- the most feared
complication in diabetes. This study's aim is to determine whether individuals who are
chronically taking selective serotonin reuptake inhibitors have a reduced ability to defend
against hypoglycemia compared to individuals not taking the medication, thus leaving them
more susceptible to hypoglycemia. Both healthy volunteers and volunteers with type 1
diabetes mellitus will be studied. The results could potentially be important to diabetic
patients, by demonstrating to physicians how to modify therapy for those taking
antidepressants in order to avoid hypoglycemia.
The known effects of SSRI on the hypothalamo pituitary axis(HPA)may be important to the
counterregulation of hypoglycemia. Prior research has demonstrated in healthy volunteers
that antecedent increases in plasma cortisol result in significant blunting of neuroendocrine
and autonomic responses to subsequent hypoglycemia. Thus, by activating the HPA axis, SSRIs
could cause blunting of the counterregulatory response to hypoglycemia.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 16 (8 males, 8 females) healthy volunteers aged 18-45 yr
- 34 (17 males, 17 females) type 1 diabetes volunteers aged 18-45 yr
- Body mass index 21-30 kg • m-2
- Normal bedside autonomic function
- Normal results of routine blood test to screen for hepatic, renal, and hematological
abnormalities
- Female volunteers of childbearing potential: negative HCG pregnancy test
- Volunteers over 40 years old: normal heart tracing recorded while resting and walking
on the treadmill
- For those with type 1 diabetes: HbA1c > 7. 0%
- For those with type 1 diabetes: had diabetes for 2-15 years
- For those with type 1 diabetes: no clinical evidence of diabetic tissue
complications
Exclusion Criteria:
- Prior history of poor health: any current or prior disease condition that alters
carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease
- Hemoglobin of less than 12 g/dl
- Abnormal results following screening tests
- Pregnancy
- Subjects with any indication of depression, anxiety, bipolar, panic, or eating
disorders
- Subjects with a past medical history or family history of mania or bipolar disorders
- Subjects unable to give voluntary informed consent
- Subjects with a recent medical illness
- Subjects with known liver or kidney disease
- Subjects taking steroids
- Subjects taking beta blockers
- Subjects on anticoagulant drugs, anemic, or with known bleeding diseases
Locations and Contacts
Vanderbilt University, Nashville, Tennessee 37232-0475, United States
Additional Information
Starting date: March 2005
Ending date: June 2009
Last updated: January 1, 2008
|